<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882219</url>
  </required_header>
  <id_info>
    <org_study_id>330704</org_study_id>
    <nct_id>NCT00882219</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period</brief_title>
  <acronym>XERES</acronym>
  <official_title>XERES Trial: Clinical Evaluation of Patients With Everolimus-eluting Stent &quot; Xience V® &quot; Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, prospective, non-randomized, non-comparative, open and multicentric study of
      patients with everolimus-eluting stent &quot; Xience V® &quot; implanted in the treatment of restenosis
      in non-coated metallic stent (BMS in-stent restenosis) during a 2 year clinical follow-up
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation by QCA (Quantitative Coronary Angiography) of in-stent late loss after the implantation of the stent XIENCE V®</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation by IVUS (Intra Vascular Ultrasound) of the in-stent volume obstruction percentage (%VO) after the implantation of a XIENCE V® stent</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by IVUS of the mean volume of neointimal hyperplasia after the implantation of a XIENCE V® stent</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by QCA of the in-stent binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the in-segment binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by QCA of in-segment late loss</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by IVUS of the in-segment % volume obstruction after the implantation of the XIENCE V® stent</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by IVUS of the rate of late incomplete apposition</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Document the number of confirmed stent thrombosis</measure>
    <time_frame>1, 8, 9, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Document the number of confirmed revascularizations (TLR, TVR)</measure>
    <time_frame>1, 8, 9, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Document the rate of MACE</measure>
    <time_frame>1, 8, 9, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Xience V®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V®</intervention_name>
    <description>Placement of a Xience V® stent within a restenosed bare metal stent.</description>
    <arm_group_label>Xience V®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older

          -  Patients affiliated to a social security or equivalent regimen

          -  Patients agreeing to participate in the study (Patient with signed informed consent )

          -  Patients with evidence of myocardial ischemia (stable or unstable angina, silent
             ischemia, positive functional exploration or a reversible modification in the ECG
             consistent with ischemia).

          -  Patient acceptable candidate for CABG surgery

          -  Patient agreeing to undergo all protocol scheduled follow-up examinations.

          -  Patients who tolerate the association Aspirin (dosed 75 to 160 mg/day) and Clopidogrel
             at 75 mg/day for at least 6 months

        Angiographic inclusion criteria:

          -  Patient with de novo and sole in-stent restenosis (focal, diffuse or proliferative) in
             a non-coated metallic stent with or without any other coronary lesions.

          -  Patient with target reference vessel diameter between 2.5 and 4 mm by visual estimate

          -  Patient with a target lesion ≤ 22mm by visual estimate

          -  Patient with a target lesion in an artery with a visual estimate of the restenosis
             between 50 and 99% and a TIMI flow grade &gt; 1

          -  Patient with multiple lesions, the other lesions have been treated with success

        Exclusion Criteria:

          -  Patient in emergency

          -  Patient pregnant

          -  Patient nursing

          -  Patient unable to give informed consent personally.

          -  Patient with myocardial infarction within the previous 72 hours.

          -  Patient with limited life expectancy (lesser than 1 year post-inclusion)

          -  Patient with unstable arrhythmia

          -  Patient with left ventricular ejection fraction (LVEF) lesser than 30%

          -  Patient receiver of a cardiac or any other organ transplantation or candidate to an
             organ transplant

          -  Patient who receive or scheduled to receive chemo- or radio- therapy within the 30
             days prior to any protocol-related procedure.

          -  Patient treated with immunosuppressives or for known immunodepressive or auto-immune
             pathologies

          -  Patient receiving chronically anticoagulant therapy with an INR greater than 2.5

          -  Patient with known hypersensitivity or contraindications to anti-platelet drugs,
             everolimus, heparin, chromium cobalt alloys, nickel, tungsten, acrylic- or fluoro-
             polymers or sensitivity to angiographic contrast agents.

          -  Patient with planned elective surgery requiring the interruption or discontinuation of
             anti-platelet therapy.

          -  Patient with platelet count &lt;100 000/ mm3 or &gt;700 000mm3 ; WBC counts &lt;3 000/mm3 or
             known or suspected liver disease

          -  Patient with severe renal insufficiency (creatinine clearance rate &lt; 30 ml/min), or
             under dialysis

          -  Patient with an history of coagulopathy refusing blood transfusion

          -  Patient who had a stroke/cerebrovascular accident or transient cerebrovascular
             ischemia in the preceding 6 months

          -  Patient with urinary or gastro-intestinal bleed in the preceding 6 months

          -  Patient with other known serious medical illness or known history of substance abuse
             (alcohol, drugs) that might result in non-compliance to the investigational plan, or
             interfere with the results or diminish the life expectancy to less than a year.

          -  Patient enrolled in an interventional study with another medical device or drug
             Angiographic exclusion criteria

          -  Patient with in-stent restenosis located on the left main on the coronary by-pass

          -  Patient with a lesion of the in-stent restenosis located in a bifurcation including a
             lateral branch of diameter &gt; 1.5mm

          -  Patient with the target vessel totally occluded

          -  Patient with a lesion of the restenosis previously treated with another device (with
             the exception of balloon-tipped catheter) such as a cutting balloon, an atherectomy,
             laser, brachytherapy or any another medicated stent.

          -  Patient with thrombus in the target vessel

          -  Patient with aorto-ostiale lesions

          -  Patient with previous failures of multiple lesions treated by angioplasty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Carrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DE RANGUEIL - CHU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de Rangueil - Chu</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stent</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Chronic coronary occlusion</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Vascular disease</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

